Bioarchitech

1 known investors

Bioarchitech develops multifunctional cancer immunotherapies derived from viral genetic code, including an intravenous engineered Vaccinia virus therapy (BA-V151) for metastatic cancer and a self-amplifying RNA intratumoural therapy (BA-R166) for early-stage cancers. Its candidates aim to both kill tumour cells and induce anti-tumour immunity, with initial focus on oesophageal and lung cancer.